Drugs / Recombinant Human Thyroid Stimulating Hormone
Recombinant Human Thyroid Stimulating Hormone
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04137185 | Jun 2019 → Dec 2020 | differentiated thyroid carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04447183 | Nov 2020 → Aug 2024 | differentiated thyroid carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06431620 | Jun 2024 → May 2026 overdue | — | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT06405217 | Apr 2024 → Mar 2026 overdue | differentiated thyroid carcinoma | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Thyroid Stimulating Hormone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04137185 ↗ |
| Known as | recombinant human thyrotropin | “recombinant human thyrotropin (rhTSH) injection” NCT06431620 ↗ |
| Known as | rhTSH | “Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)” NCT04447183 ↗1“recombinant human thyrotropin (rhTSH) injection” NCT06431620 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Thyroid Stimulating Hormone for Injection” NCT04137185 ↗ |
| Route | Intramuscular | “intramuscularly (IM)” NCT04137185 ↗ |